Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index; 4 of the 9 sources its claims cite were checked for support.

Comparison of Five Assays for the Detection of Anti-dsDNA Antibodies and Their Correlation with Complement Consumption

Open access
Ricchiuti, Vincent, Obney, Jacob, Holloway, Brooke, Aure, Mary Ann, Shapiro, Marti, Bentow, Chelsea, Mahler, Michael·2025·Diagnostics

Abstract

Background: Anti-dsDNA is an important biomarker for the diagnosis, prognosis, and monitoring of systemic lupus erythematosus (SLE). Although several assays for anti-dsDNA antibody detection are routinely used, standardization remains limited, and differences have been reported. This study aimed to compare five methods for anti-dsDNA antibody detection and to estimate their association with complement consumption. Methods: A total of 149 samples submitted for routine laboratory testing were collected and tested on five platforms: Crithidia luciliae indirect immunofluorescence test (CLIFT), addressable laser bead immunoassay (ALBIA), a high-avidity (HA) enzyme-linked immunosorbent assay (ELISA), chemiluminescent immunoassay (CIA), and a novel particle-based multi-analyte technology (PMAT). Complements C3 and C4 were available for a subset of the total samples. Results: Correlation between anti-dsDNA assays ranged from 0.94 (CIA and PMAT) to 0.65 (ALBIA and CLIFT). The AUC from the ROC analysis using CLIFT as a reference was 0.95 for PMAT, 0.94 for CIA, 0.93 for ELISA, and 0.86 for ALBIA. The highest sensitivity relative to CLIFT at a fixed specificity of 94.4% was 84.7% for CIA and ELISA, 76.3% for PMAT, and 42.4% for ALBIA. Correlation between anti-dsDNA and C3 ranged from −0.81 for ELISA to −0.51 for ALBIA. Conclusions: Different anti-dsDNA detection methods showed varying diagnostic performance and correlation and varying agreement with CLIFT and complement consumption. ELISA, CIA, and PMAT showed high correlation to each other and to CLIFT and were in strong concordance with low C3 levels. In contrast, ALBIA revealed lower clinical performance and correlation with CLIFT and complement consumption.

Overview

CoChat Summary

## TL;DR

This study compared five anti-dsDNA antibody assays in 149 routine serum samples and found that ELISA, CIA, and PMAT agreed best with each other and with CLIFT, while ALBIA performed worse. Using C3 and C4 as surrogates for disease activity, ELISA, CIA, and PMAT also showed stronger inverse correlations with complement consumption than ALBIA.

## Key findings

  • Among 149 samples, 50 (33.6%) were negative across all five platforms, and 48 (32.2%) were positive across all five methods.
  • Pairwise assay correlation ranged from Spearman’s ρ = 0.65 for ALBIA vs. CLIFT to 0.94 for PMAT vs. CIA.
  • Using CLIFT as the reference, ROC AUCs were 0.95 for PMAT, 0.94 for CIA, 0.93 for ELISA, and 0.86 for ALBIA.
  • At fixed specificity of 94.4%, sensitivity relative to CLIFT was 84.7% for CIA and ELISA, 76.3% for PMAT, and 42.4% for ALBIA.
  • For complement consumption, anti-dsDNA vs. C3 correlations were strongest for ELISA (−0.81), then CLIFT (−0.76), CIA and PMAT (both −0.70), and weakest for ALBIA (−0.51); C4 showed the same ranking pattern.

## Methods

  • Retrospective comparison of five anti-dsDNA assays on 149 routine serum samples collected at Labcorp; samples came from 113 female patients, 34 male patients, and 2 with missing demographic data.
  • Assays tested were CLIFT, HA ELISA, ALBIA, CIA, and PMAT; Farr assay was excluded because of limited current use.
  • Concordance was assessed with Spearman correlation, ROC/AUC analysis using CLIFT as the binary reference, overlap plots, and comparisons against C3/C4 values available for subsets of samples (C3 for 49, C4 for 48).

## Limitations

  • The paper states that clinical data, specifically SLE diagnoses, were unavailable for the included patients.
  • The paper states that complement data were available only for a limited number of patients: 49 for C3 and 48 for C4.
  • Evident from the text: the sample was from routine testing at a single large U.S. reference laboratory, and the design was based on available residual samples rather than a controlled case-control cohort, which limits direct disease-level inference.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/diagnostics15192430

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 UpSet plot demonstrating the overlap between anti-dsDNA antibodies measured using different methods.
Figure 1 UpSet plot demonstrating the overlap between anti-dsDNA antibodies measured using different methods.CC BY · PubMed Central
Figure 2 Left panel: heatmap showing the correlation between five anti-dsDNA antibody assays. The highest correlation was found for CIA vs. PMAT and the lowest correlation for ALBIA vs. CLIFT. Right panel: column heatmap showing relative correlations of four assays to CLIFT, which was set to 1.00. The highest correlation with CLIFT was found for CIA, closely followed by PMAT and ELISA, and then ALBIA.
Figure 2 Left panel: heatmap showing the correlation between five anti-dsDNA antibody assays. The highest correlation was found for CIA vs. PMAT and the lowest correlation for ALBIA vs. CLIFT. Right panel: column heatmap showing relative correlations of four assays to CLIFT, which was set to 1.00. The highest correlation with CLIFT was found for CIA, closely followed by PMAT and ELISA, and then ALBIA.CC BY · PubMed Central
Figure 3 Receiver operating characteristic (ROC) analysis of the four immunoassays (ELISA, ALBIA, CIA, and PMAT) using CLIFT as a binary classifier.
Figure 3 Receiver operating characteristic (ROC) analysis of the four immunoassays (ELISA, ALBIA, CIA, and PMAT) using CLIFT as a binary classifier.CC BY · PubMed Central
Figure 4 Column heatmap showing relative correlations of five assays to C3, which was set to a value of 1.00. The highest correlation was found for ELISA, followed by CLIFT, CIA, PMAT, and then ALBIA.
Figure 4 Column heatmap showing relative correlations of five assays to C3, which was set to a value of 1.00. The highest correlation was found for ELISA, followed by CLIFT, CIA, PMAT, and then ALBIA.CC BY · PubMed Central
Figure 5 Graphics showing a change in usage of methods for anti-dsDNA testing for the years 2009–2017 based on the results of the UKNEQAS results for anti-dsDNA sample distributions [5]. In (A) the relative proportion of the different methods is shown (from 2009). In (B) the compound average growth rates (CAGR, in percent) are displayed [5]. This content is copyright of Werfen—© Werfen 2018 All Rights Reserved. Note: Different nomenclature/abbreviations were used for the following assays in this figure: IFA = immunofluorescence assay; CLIA = chemiluminescence immunoassay.
Figure 5 Graphics showing a change in usage of methods for anti-dsDNA testing for the years 2009–2017 based on the results of the UKNEQAS results for anti-dsDNA sample distributions [5]. In (A) the relative proportion of the different methods is shown (from 2009). In (B) the compound average growth rates (CAGR, in percent) are displayed [5]. This content is copyright of Werfen—© Werfen 2018 All Rights Reserved. Note: Different nomenclature/abbreviations were used for the following assays in this figure: IFA = immunofluorescence assay; CLIA = chemiluminescence immunoassay.CC BY · PubMed Central

Verification

Claims the paper makes

4 Valid · 0 Not valid · 3 Not checked · 31 Own results and interpretations

10 more claims

Create a free account to see all 38 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 21
  • Probably not a substantial claim. 3

Create a free account to see these claims.

Citations

Cites

Show all 24 references

Cited by

See all 3

Metadata

Authors
Ricchiuti, V., Obney, J., Holloway, B., Aure, M. A., Shapiro, M., Bentow, C., & Mahler, M.
Affiliations
  • LabCorp (United States) (US)
  • Werfen (United States) (US)
  • Research and Development, Werfen Autoimmunity, San Diego, CA 92131, USA
Corresponding author
Ricchiuti, Vincent
Venue
Diagnostics
Publisher
MDPI AG
Published
2025-09-24
Volume
15
Issue
19
Pages
2430
ISSN
2075-4418 (ISSN-L)
OpenAlex
W4414479530
Cited by
3
References
24
Citations by year
2026: 3
FWCI
2.19
Type
journal article
Language
en
Open access
Locations
  • Diagnostics (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
  • Health Sciences › Health Professions › Medical Laboratory Technology › Clinical Laboratory Practices and Quality Control
  • Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
Keywords
anti-dsDNA antibodies, systemic lupus erythematosus, complement consumption, complement C3, C4, assay comparison, indirect immunofluorescence, chemiluminescence immunoassay, diagnostic performance, standardization

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparison of Five Assays for the Detection of Anti-dsDNA Antibodies and Their Correlation with Complement Consumption. https://app.cochat.ai/papers/10.3390/diagnostics15192430
The paper
Ricchiuti, V., Obney, J., Holloway, B., Aure, M. A., Shapiro, M., Bentow, C., & Mahler, M. (2025). Comparison of Five Assays for the Detection of Anti-dsDNA Antibodies and Their Correlation with Complement Consumption. Diagnostics. https://doi.org/10.3390/diagnostics15192430

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.